Project Grant R56NS117926

This $460,940 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program aims to investigate the impact of glioma-associated germline risk alleles on neurodevelopmental trajectories. The research will leverage single-cell and bulk profiling approaches in human induced pluripotent stem cell (iPSC) and knock-in mouse models to interrogate the epigenetic and...

The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $877,001 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to The Washington University in St. Louis to support research aimed at "Modeling Neurofibromatosis-1 Disease Heterogeneity to Optimize Risk Assessment and Treatment." The project will leverage patient-derived and genetically-engineered human cell models, as well as mouse models with...

This $734,542 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports research to develop novel biomarkers for measuring plexiform neurofibroma tumor burden in individuals with neurofibromatosis type 1 (NF1). The key products and services to be delivered under this award include: Analytical validation studies to evaluate candidate...

The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $160,500 Project Grant (CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders) to Children's Hospital Medical Center in Cincinnati, Ohio. The grant supports research to investigate the epigenetic mechanisms underlying neurodevelopmental defects in Menke-Hennekam Syndrome, a rare genetic disorder caused by mutations in the EP300 gene. The project aims to (1) identify maturation and...

This federal Project Grant award of $656,513.00, awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to identify germline modifiers of neurofibromatosis type 1 (NF1) tumors. The primary grantee, Childrens Hospital Medical Center, will work with a multidisciplinary team to expand the patient cohort with plexiform neurofibromas and/or optic...

This $167,584 federal Project Grant awarded by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) to the University of California, San Diego supports research to investigate the underlying biology driving atypical teratoid rhabdoid tumors (ATRTs), aggressive pediatric brain cancers. The key products and services to be delivered include: Leveraging a human induced pluripotent stem cell (hiPSC) platform with inducible SMARCB1 knockdown to characterize interactions between...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, provides $699,559 to Merlin Therapeutics Inc. to develop a novel adeno-associated viral vector 9 (AAV9) gene therapy for the treatment of neurofibromatosis type 2 (NF2). The therapy aims to express a healthy copy of the NF2 gene and rescue tumor characteristics in NF2...

The Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), awarded a $858,033 Project Grant to the Children's Hospital Medical Center in Cincinnati, Ohio. The grant, titled "TARGETING SCHWANN CELL-IMMUNE INTERACTIONS IN NEUROFIBROMATOSIS TYPE 1", will fund research focused on improving treatment approaches for neurofibromatosis type 1, a genetic disorder that causes tumor growth in the nervous system. The grant award period runs from...

This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is providing $698,459 to Epitor Therapeutics, Inc. to develop novel epigenetic editing tools to treat Rett syndrome. The funding will support research to optimize an epigenetic editor comprised of a catalytically dead Cas (dCas) protein fused with a miniature TET demethylase...

This National Institute of Neurological Disorders and Stroke (NINDS) Project Grant award under CFDA 93.853, Extramural Research Programs in the Neurosciences and Neurological Disorders, provides $190,485 to the Trustees of Indiana University (Indiana University Indianapolis) to investigate the molecular mechanisms underlying differentiation failure in neuroepithelial stem cells with NF2 gene mutations. The primary objectives are to: (1) identify the cellular hierarchy in NF2-deficient stem cells...